The FDA recently approved Genentech’s Lucentis (ranibizumab injection) for the monthly treatment of all forms of diabetic retinopathy (DR). The recent approval came after a Priority Review based on an analysis of the DRCR.net’s Protocol S study. The study compared Lucentis treatment with panretinal laser photocoagulation in DR patients with and without DME, and found the Lucentis group experienced improvements in retinopathy severity.
|Genentech. FDA approves Genentech's Lucentis (ranibizumab Injection) for diabetic retinopathy, the leading cause of blindness among working age adults in the United States. April 17, 2017.|